Key facts
- This page summarizes Padmavathi Sundar's Form 4 filing for Oncocyte Corp (OCX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Mar 2022, 21:24.
Padmavathi Sundar - 15 Mar 2022 Form 4 Insider Report for Oncocyte Corp (OCX)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- OCX
- Reported as of
- 15 Mar 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Padmavathi Sundar
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Padmavathi Sundar filed Form 4 for Oncocyte Corp (OCX) on 17 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCX
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +87,500
- Change %
- Price
- $0.000000
- Shares after
- 87,500
- Date
- 15 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,500
- Exercise price
- $1.15
- Footnotes
- F1
OCX
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +87,500
- Change %
- Price
- $0.000000
- Shares after
- 87,500
- Date
- 15 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,500
- Exercise price
- $1.15
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
Footnote F2
Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.